Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
BioIVT
BioIVT
Activities:
Research & Development
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
KBI Biopharma extends contract with a big pharma giant after a successful FDA inspection
The contract has been renewed and extended until at least 2029, and will now include the purchase of two therapeutic products
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
New FAIRY viral assay could 'revolutionise' the response to future pandemics
The assay, which can detect the infectiousness of a virus in a matter of minutes, offers a quicker and cheaper alternative to the standard cell culture approach
New advice from BOLA and Labtex on cleaning and handling of PTFE products after use
The companies share: "Abrasive scouring agents may result in a milkiness of the vessels made of PFA and FEP. You may use all neutral detergents (pH 7). For higher contamination...
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Manufacturing
BioIVT acquires supplier of "human biological material" for in vitro
PrecisionMed is a leading supplier of high-quality human biological material for genetics, drug discovery, and biomarker research and in vitro diagnostics
Research & Development
BioIVT acquires Fidelis Research
The transaction increases BioIVT's network and allows it to extends to deliver fresh biospecimens and produce cell products for drug and diagnostic development
Research & Development
BioIVT acquires Cypex, a leading manufacturer of drug-metabolising enzymes
Cypex’s recombinant xenobiotic metabolising enzymes complement BioIVT’s extensive portfolio of hepatocytes and related hepatic products for drug research and development
Research & Development
BioIVT appoints Senior VP, Global Commercial Operations
Jennifer Murphy has more than 16 years’ experience in the diagnostics and life sciences industries
Research & Development
BioIVT hosting open house at London blood donor centre
The company’s Wood Lane location has expanded apheresis, whole blood, and plasma collection capabilities, as well as an on-site cell isolation laboratory
BioIVT appoints new COO
Lori Ball will move from her role as President and CEO of LAB Strategies take up the role at the provider of research models and services for drug and diagnostic development
Research & Development
Study uses fresh method to evaluate botanical-drug interactions
A whole cell model using Transporter-certified hepatocytes in sandwich culture has demonstrated that false positives might be a risk with the traditional method of analysis
Subscribe now